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Abstract The prostate gland is exquisitely sensitive to
androgen receptor (AR) signaling. AR signaling is oblig-
atory for prostate development and changes in AR levels,
its ligands or shifts in AR mode of action are reflected in
the physiology of the prostate. The AR is intimately linked
to prostate cancer biology through the regulation of epi-
thelial proliferation, suppression of apoptosis and the
development of castration-resistant disease. Thus, AR is
the primary therapeutic target in various prostate diseases
such as BPH and cancer. Although some tumors lose AR
expression, most retain the AR and have elevated levels
and/or shifts in activity that are required for tumor pro-
gression and metastasis. New AR inhibitors currently in
clinical trials with higher receptor affinity and specificity
may improve prostate cancer patient outcome. Several
events play an important role in initiation, primary tumor
development and metastatic spread. Androgen receptor
activity and promoter specificity change due to altered
coregulator expression. Changes in epigenetic surveillance
alter the AR cistrome. Both systemic and local inflamma-
tion increases with PCa progression affecting AR levels,
activity, and requirement for ligand. Our current under-
standing of AR biology suggest that global androgen sup-
pression may drive the development of castration-resistant
disease and therefore the question remains: Does effective
inhibition of AR activity mark the end of the road for PCa
or only a sharp turn toward a different type of malignancy?
Keywords Androgen receptor  Prostate cancer 
Castration resistance  Metastasis
Introduction
Prostate cancer (PCa) originates in the epithelial compart-
ment of the prostate, an organ dependent on androgen
receptor (AR) signaling for its development, maintenance
and physiological function. It is not clear which early
oncogenic events lead to neoplastic transformation, but due
to the heterogeneity of PCa there are likely numerous ini-
tiating factors. While there is some hereditary component
associated with PCa incidence, the major risk factor for the
development of this malignancy is age. Two major hall-
marks of aging in men are decreasing levels of testosterone
and elevated levels of inflammatory cytokines, including
interleukin-6 (IL-6). Systemic inflammation suppresses
testosterone secretion and testosterone supplementation has
been shown to reduce the levels of inflammatory cytokines
in hypogonadal men [1]. On the other hand, IL-6 can acti-
vate AR at suboptimal levels of androgens and indepen-
dently of its ligands potentially causing a shift in the AR
cistrome and transcriptome. Analysis of 218 PCas demon-
strated that the AR pathway is activated in 56% of primary
and 100% of metastatic PCas [2]. Thus, it is plausible that
AR is a key or at the very least an obligatory accessory
protein in PCa initiation and its function continuously
changes with progression. Dramatic changes occur in a
variety of cell signaling processes with PCa progression
(Fig. 1). In this review, we will limit our discussion to
changes in AR function observed in PCa patients and
mechanistically substantiated in cell lines or mouse models.
Primary tumors
In the normal prostate, AR is expressed in both epithelial
and stromal compartments as well as in endothelial cells.
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AR is a transcription factor that can be activated by a wide
range of natural ligands such as testosterone, dihydrotes-
tosterone, estradiol, as well as independently of ligand by
inflammatory and growth hormone receptor pathways.
Upon activation, AR binds to androgen response elements
(AREs) in the promoter, enhancer and intronic regions of
androgen regulated genes frequently guided by pioneer
factors [3]. Once bound to regulatory regions, AR assem-
bles a complex of coregulators that modify chromatin,
general transcription machinery, and other proteins that
regulate transcription [3]. During PCa progression both AR
activity and target gene specificity change causing a shift in
AR function from pro-differentiation to pro-proliferation.
AR levels
AR expression in primary tumors correlates significantly
with an increased proliferative index and markers of
aggressive disease and patients with higher levels of AR
recur and ultimately die of PCa significantly faster [4, 5].
Using mouse xenograft models, Chen et al. monitored
changes associated with the development of castration
resistance in seven independently derived androgen
dependent PCa cell lines. Remarkably, they found a single
consistent change, increased expression and protein levels
of AR [6]. Overexpression of AR in PCa cells stimulated
proliferation at suboptimal levels of androgens and helped
overcome the inhibitory effect of bicalutamide [6].
However, overexpression of wild-type AR in luminal
epithelial cells of the mouse caused high-grade prostatic
intraepithelial neoplasia (PIN), without the development
of overt carcinoma [7], suggesting that for PCa develop-
ment both elevated AR levels and changes in activity are
required.
AR Cistrome
AR binding sites on the chromatin are collectively called
the AR cistrome. These sites are frequently marked by
specific chromatin modifications introduced by pioneer
factors such as OCT1, GATA2 and FOXA1 prior to hor-
mone treatment. In LNCaP cells over half of the AR
binding loci are also bound by FOXA1. On most of these
sites, FOXA1 binds before hormone treatment and AR
recruitment. Interestingly, FOXA1 ablation causes massive
reprogramming of the AR cistrome: 40% of loci are pre-
served with increased level of AR recruitment, the
remaining 60% of loci are lost, and many new AR binding
sites appear, causing the AR cistrome to increase more than
fourfold with corresponding changes in gene expression
Fig. 1 Alterations in AR function in PCa and the development of
CRPC. Classical ligand-dependent AR action and interplay between
various intracellular signaling pathways in primary tumors (Left).
Following androgen ablation, increased AR levels and a dramatic
shift in AR function is observed ultimately leading to the develop-
ment of CRPC (Right). Red boxes and arrows indicate increased
levels and/or activation of signaling pathways. Green boxes denote
factors that are lost during the progression of PCa. The TMPRSS2-
ERG fusion event is present in 60% of PCas and is indicated by the
dashed lines. Dotted lines indicate cross talk with the AR
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[8]. A modest but highly significant reduction in FOXA1
mRNA expression in two PCa cohorts is significantly
associated with metastatic PCa and poor prognosis [8].
High nuclear accumulation of FOXA1 protein is also
associated with metastatic disease [9]. Thus, changes in
FOXA1 expression and distribution may change the AR
cistrome and consequentially its function, which is fre-
quently observed during the progression of PCa.
AR activity
AR activity can be altered through a number of different
mechanisms: receptor mutations, alternative splicing of AR
mRNA, changes in the levels of coactivator and core-
pressors, and activation of cell signaling pathways (Fig. 1).
Mutations and splicing
A significant portion of PCas bear somatic mutations of AR
that affect its ligand specificity, interaction with coregula-
tors, dimerization, stability, and other AR properties [10].
In a mouse model, expression of an AR E231G mutant that
has altered coregulator interactions caused rapid develop-
ment of metastatic PCa with 100% penetrance [11]. AR
splice variants (ARV), which typically lack the ligand
binding domain of the receptor and do not require agonist
for activity, were first identified in CWR22R PCa cells and
subsequently PCa specimens. Expression of these variants
is often induced by castration and associated with tumor
progression to CRPC [12]. Elevated ARV levels have been
observed in patients who failed hormone therapies pro-
viding survival and growth advantage by acting coopera-
tively with full length AR [13]. In in vitro and xenograft
models, various ARVs confer both resistance to castration
associated tumor atrophy and promote growth in androgen-
depleted conditions [14]. Elevated ARV expression
potentially disturbs cell cycle regulation and creates a shift
in the AR transcriptome [14, 15]. FOXA1 directly interacts
with the AR through the hinge region, which is lost or
altered in many ARVs. Therefore, some mutants and splice
variants may provide a survival and growth advantage in
androgen-depleted conditions by shifting the AR tran-
scriptome via circumventing FOXA1 regulation of AR
genomic targeting [8].
Cell Cycle
Androgens promote proliferation through signals that
modulate critical regulators of the cell cycle. For the most
part, the AR regulates the cell cycle through induction of
signals that regulate G1-S phase transition through the
promotion of G1 cyclin-dependant kinases (CDKs) and
inhibition of the retinoblastoma (Rb) tumor suppressor
gene [16]. Androgens also regulate the transcription and
turnover of the cell cycle regulators p21Cip1 and p27Kip1.
The M-phase checkpoint protein UBE2C, a direct target of
the AR, is significantly overexpressed in CRPC. In addi-
tion, AR displays ligand independent recruitment to the
UBE2C loci in ablation-resistant PCa cell lines concurrent
with elevated UBE2C expression [17].
Coactivators
Coregulators are integral to the normal function of steroid
receptors and the development and progression of a wide
spectrum of human diseases [18]. AR coregulators stimu-
late or decrease AR activity in a promoter specific manner
[19]. Therefore, changes in particular coregulator expres-
sion and regulation will have distinct effects on AR target
genes and the AR transcriptome.
AR is potentiated by the p160 family of coactivators
that include SRC-1 (NCOA1), TIF2 (NCOA2), and
SRC-3 (AIB1, NCOA3). In the normal prostate, SRC-1
expression is uniform throughout the prostate but varies
considerably between men. Levels of SRC-1 do not
change with the development of PCa but men that have
higher SRC-1 expression will develop more aggressive
PCas [20]. TIF2 expression in normal prostate is low to
undetectable. With primary PCa, development expression
of TIF2 increases from low to high-grade tumors and
recurrent CRPCs have the highest uniformed expression
of TIF2 [21]. The AR directly binds to the TIF2 promoter
and an intron and represses TIF2 expression. Reduced
androgen levels increase TIF2 expression and it becomes
available to potentiate AR and other transcription factors
stimulating both AR dependent and AR independent
proliferation [21]. Thus, androgen ablation itself may
cause increased TIF2 expression and contribute to the
development of CRPC. The TIF2 gene is positioned at
8q13.3 in close proximity to MYC at 8q24.21; these
regions are most frequently amplified in PCa [2]. Con-
sistent with our protein expression studies, Taylor et al.
found positive copy number alterations through amplifi-
cation and overexpression of TIF2 in 8% of primary
tumors and 37% of metastases [2]. Significantly, primary
tumors with amplification of TIF2 display an increase in
AR signaling [2]. SRC-3 expression is similar throughout
the same prostate but varies greatly between patients [22].
Similar to SRC-1, elevated levels of SRC-3 in normal
prostate is a predictor of the development of more
aggressive PCa but its expression is significantly
increased with the development of primary tumors [22].
In addition to activating AR transcriptional activity, SRC-3
coactivates AP1 and PEA3 transcription factors [23]. Akt is
a direct transcriptional target of AP1 and increased
SRC-3 expression increases total and phospho-Akt levels;
World J Urol (2012) 30:279–285 281
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increased expression of SRC-3 in PCa correlates signifi-
cantly with pAkt levels in PCa specimens as well as
increased proliferation and reduced apoptosis [22, 23]. In
addition, SRC-3 stimulates cellular motility by activating
focal adhesion kinase signaling and invasion by activating
AR, AP1 and PEA3 dependent expression of matrix
metalloproteinases 2 and 13 [23].
Inflammation
As men age, circulating levels of inflammatory cytokines,
including IL-6, tumor necrosis factor a (TNF-a) and
interleukin-1b (IL-1b), increase along with PCa incidence
[1, 24]. Particular focus has been on IL-6, since IL-6 has
been shown to potentiate AR function. Regions of focal
atrophic prostatic epithelium in aging men are common and
are often associated with inflammation. These lesions,
termed proliferative inflammatory atrophy (PIA), typically
display increased epithelial proliferation, are associated
with PIN and proposed to be precursors of PCa [24]. In
benign prostate epithelium, IL-6 is expressed in basal cells,
but in PIN and PCa its expression is detected in the
secretory epithelium [25]. The highest circulating levels of
IL-6 are observed in patients with CRPC and metastatic
disease [26]. Increased IL-6 levels are associated with
markers of PCa progression and poor prognosis such as
androgen independent growth, resistance to chemothera-
peutic drugs and neuroendocrine differentiation. In vitro
studies show that IL-6 can both inhibit and promote the
proliferation of AR expressing LNCaP PCa cells depending
on the cellular context and ligand availability [26, 27]. IL-6
activates ligand independent AR activity via STAT3 and
overexpression of IL-6 can protect LNCaP cells from
growth arrest and apoptosis induced by androgen starvation
[27].
One of the major conduits of inflammation is the NF-jB
(nuclear factor kappa-light-chain-enhancer of activated B
cells) family of transcription factors. Elevated NF-jB
activity in primary PCas is associated with poor prognosis
and reduced time to biochemical recurrence [28]. Contin-
uous activation of the NF-jB pathway in vivo inhibits
prostate regression following castration, maintains nuclear
AR and sustains epithelial proliferation [28]. In human PCa
cell lines, NF-jB signaling interferes with cell cycle arrest
and apoptosis mediated by androgen deprivation and
stimulates AR ligand independent transcriptional activity
and recruitment of coactivators such as p300 [29]. Inter-
estingly, processing the NF-jB family member p100 to
produce p52 requires STAT3, a downstream signaling
target of IL-6 and conversely IL-6 is a NF-jB target.
Therefore, prostatitis and PCa associated inflammation
likely aid in the development and progression of PCa by
modulating AR function.
AR, reactive stroma, and PCa progression
In the normal stroma, AR stimulates secretion of paracrine
factors that regulate the proliferation and survival of the
epithelium. The stromal compartment of the prostate
undergoes significant changes with PCa progression and
both expansion and loss of the stroma signals poorer
prognosis [30]. Recent studies indicate that reduced perit-
umoral expression of stromal AR is associated with nega-
tive clinical parameters and significantly earlier relapse
following radical prostatectomy [31]. Loss of stromal AR
likely promotes cancer progression through deregulation of
stromal factors required for normal growth and differenti-
ation of the epithelium. In PCa, stroma often becomes
reactive characterized by a reduction in well differentiated
smooth muscle cells and increased deposition of extracel-
lular matrix and collagen fibrils. Patients who have more
than 85% of intra-tumoral reactive stroma are at 17.13
times higher risk of biochemical recurrence [32]. Reactive
stroma promotes invasion and metastasis of PCa. A number
of stromal paracrine factors have been implicated in PCa,
including transforming growth factor b (TGF-b), which is
known to cross-talk with the AR. TGF-b and AR signaling
cooperate to maintain the differentiated state of the stroma
in the benign prostate. In the normal prostate, stromal
TGF-b signaling is anti-proliferative, pro-apoptotic and
enhances differentiation of the luminal epithelium. In
malignant epithelial cells, AR suppresses TGF-b receptor
II (TbR-II) transcription and reduces TGF-b1 driven
apoptosis [33]. Furthermore, AR impedes TGF- b1 sig-
naling in the epithelium through direct interaction and
transcriptional suppression of SMAD3 [33]. These data
suggest that AR action in malignant epithelial cells pro-
vides a growth advantage by suppressing TGF mediated
pathways. Therefore, androgen ablation therapies, which
suppress epithelial AR mediate proliferation, also likely
suppress beneficial stromal AR activity and contribute to
the progression and establishment of CRPC.
Metastatic dissemination
It is becoming evident that tumor dissemination occurs
early in PCa development. The first wave of cancer cell
shedding occurs during primary tumor growth. The abun-
dance of circulating tumor cells (CTC) is predictive of
patient prognosis [34]. CTC analysis revealed that these
cells have the same TMPSS2-ERG fusion status as primary
tumor but increased heterogeneity of AR levels and PTEN
loss [35], suggesting that these alterations may be sub-
sequent to the fusion event. If indeed TMPRSS2-ERG
fusion occurs early in tumorigenesis, its expression is then
significantly increased by AR signaling. Overexpression of
282 World J Urol (2012) 30:279–285
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the oncogenic transcription factor ERG under an AR
responsive promoter causes profound changes: Reduction
in AR expression, attenuation of AR activity at gene spe-
cific loci, activation of NF-jB, and induced expression of
epigenetic factors such as the methyltransferase EZH2 that
in turn epigenetically silences differentiating factors and
tumor suppressors, such as Nkx3.1 and DAB2IP [36, 37].
While a number of different fusions events between
TMPRSS2 and ETS family members have been identified
and implicated in the progression of PCa, TMPRSS2-ERG
is the most common and has the biggest impact on
prognosis.
The luminal secretory epithelium is characterized, in
part, by polarized orientation, cohesive extracellular
interaction between like cells, and relative immobility of
those cells in respect to the basal membrane. This pheno-
type is maintained by adhesion molecules such as a- and
b-catenin, which connect the actin cytoskeleton to intra-
cellular domains of cadherins. Loss or down regulated of
critical adhesion molecules enables cells to detach from
their epithelial scaffold and move more freely within the
extracellular matrix. When b-catenin translocates to the
nucleus it can coactivate both AR and TCF/LEF tran-
scription factors that induce epithelial to meshenchyme
transition (EMT) markers Slug and Twist. Following cas-
tration in mouse, PCa xenografts b-catenin relocated to the
nuclei of LNCaP cells. Survival rates are significantly
shorter among PCa patients if b-catenin is not exclusively
localized to the cell membrane and b-catenin expression is
lost in metastasis [38, 39]. Multiple studies have shown
that loss of E-cadherin expression and translocation of
b-catenin from the leading edge of the cell to the nucleus
accompanies the transition to a mesenchymal phenotype in
vivo [40–42]. Although some controversy still exists con-
cerning the incidence of EMT in cancer, the concept is
supported by the observation of aberrant E-cadherin and
b-catenin expression in metastatic PCas [40, 43].
Role of AR in development of castration-resistant
prostate cancer (CRPC)
Following the spread of PCas the standard of care is
androgen ablation. Ablation is effective at first, but PCa
almost always recurs as CRPC, suggesting that inhibiting
AR activity activates pro-survival mechanisms. While it is
not known which mechanisms are activated in individual
PCa patients, expression data implicates several key path-
ways. As mentioned previously, castration elevates levels
of TIF2 and p300, and ligand independent activators such
as IL-6. In addition, one of the negative regulators of Akt
action, INPP4B, is a direct AR target gene [44] and is
likely lost during castration. Indeed, activation of Akt
signaling follows androgen ablation in men. In mouse
models, activation of Akt can cause development of PIN
even in the absence of AR signaling [45] while synergistic
activation of Akt and AR is sufficient to cause frank car-
cinoma [46]. In addition, TMPRSS2-ERG fusion causes
increased EZH2 signaling, associated with metastatic
spread and recurrence.
Conclusions
The AR clearly represents a central hub in the regulation of
normal prostate biology and the development, progression,
therapeutic resistance and metastatic spread of PCa. Tar-
geting the AR remains the central focus of PCa therapeu-
tics and basic research. Despite this central role,
therapeutic targeting of the AR has yet to prove fully
successful. Our current and ever evolving understanding of
the AR its cross-talk with intracellular signaling pathways
and its compartmental functions will hopefully shed light
on selective treatment targets. The selective targeting of
key regulators and/or mediators of AR function in addition
to or as an alternative to global AR ablation should provide
customized patient care and improved outcomes.
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